口服丁酸盐对IBD临床和生物化学参数的影响:一项针对肠道微生物群的随机化安慰剂对照研究
Sonia Facchin1, Matteo Calgaro2, Mattia Pandolfo2
1Department of Surgery, Oncology and Gastroenterology (DISCOG), University Hospital of Padua, Padua, Italy; Gastroenterology Unit, Azienda Ospedale Università di Padova, Padova, Italy.
概括
丁酸盐-Lsc-微囊 (BLM) 补充剂改变了炎症性肠病 (IBD) 患者的肠道微生物群. 这种调节导致了疾病活性和生活质量的显著改善,特别是在特定的肠类型中.
科学领域:
- 胃肠病学 胃肠病学
- 微生物组研究 微生物组研究
- 临床治疗学 临床治疗学
背景情况:
- 炎症性肠病 (IBD) 包括克罗恩病 (CD) 和性结肠炎 (UC),其特点是慢性肠道炎症.
- 肠道微生物组失调症与IBD的发病和进展有关.
- 准肠道微生物群是IBD的潜在治疗策略.
研究的目的:
- 研究酸盐-Lsc-微囊 (BLM) 补充剂对IBD患者肠道微生物组合的影响.
- 评估BLM对临床疾病活性,便calprotectin (fCal) 水平和生活质量 (QoL) 的影响.
- 识别可能对BLM疗法产生偏好反应的潜在肠型.
主要方法:
- 一个随机,双盲,安慰剂对照试验,涉及140名IBD患者 (60CD,80UC).
- 患者接受了口服BLM补充剂与常规治疗一起.
- 便样本通过16S测序分析微生物组合 (Firmicutes/Bacteroidota比率) 和fCal水平.
- 使用哈维-布拉德肖指数 (HBI) 评估的临床疾病活动CD和UC部分Mayo-Score;QoL通过炎症肠病问卷-32 (IBDQ) 测量.
主要成果:
- 在CD和UC患者中,通过Firmicutes/Bacteroidota (F/B) 比率定义的两个主要肠型被确定.
- BLM对肠型1 (低F/B比率) 产生了更大的影响,导致了更大的临床和生化改善.
- 在CD患者中观察到临床疾病活性 (p=0.013) 和fCal (p=0.047) 的显著改善.
- 在CD (p<0.001) 和UC (p=0.003) 患者中,生活质量 (QoL) 显著提高.
- 在UC患者中观察到fCal的边际减少 (p=0.09).
结论:
- 酸盐-Lsc-微囊 (BLM) 补充剂调节IBD患者的肠道微生物群.
- BLM治疗导致疾病结果和生活质量的显著改善.
- 肠类型1 (低F/B比率) 可能代表BLM干预IBD的目标人群.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
617
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
617
Inflammatory Bowel Disease IV: Pharmacological Management
450
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
450
Drugs for Treatment of Constipation-Predominant IBS
680
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
680
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
710
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
710
Drugs for Treatment of Ulcerative Colitis in IBD
431
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
431
Bacterial Flora of the Large Intestine
1.5K
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
1.5K


